Arrowhead plans regulatory filing for plozasiran in sHTG

Biopharmaceutical company Arrowhead Pharmaceuticals has announced its intention to submit a regulatory application for its investigational drug plozasiran. The treatment is intended for severe hypertriglyceridemia, a condition characterized by very high levels of triglycerides in the blood.

This story was originally reported by Investing.com. As an automated real-time news aggregator, NewsToolBar provides multi-perspective indexing and AI summarization while directing full readership directly to primary publisher sources.